National Drug Code Directory



Similar documents
Content of Labeling/Product Data Elements SPL Technical Errors Training ebook

Registration of Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act. Guidance for Industry

Recommended Warning for Overthe-Counter. Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) September 2009 OTC

OV E R V I E W A N D G U I D A N C E O N VACC I N E 2 D B A R CO D I N G

Guidance for Industry Bar Code Label Requirements Questions and Answers

CENTER FOR DRUG EVALUATION AND RESEARCH Orig1s000

Guidance for Industry

Guidance for Industry

Guidance for Industry

Guidance for Industry Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator,

Guidance for Industry

IACP Comparison of 503A and 503B The Drug Quality and Security Act of 2013

Marketed Unapproved Drugs: FDA to Take Immediate Enforcement Action at Any Time, Without Prior Notice

NDA /S-008 SUPPLEMENT APPROVAL

Guidance for Industry

Average Sale Price (ASP) Data Collection Template/Data Validation Macro User Manual

Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry

NDA NDA APPROVAL

Coding Systems. Understanding NDC and HCPCS. December 2014

Application Submitted on Received on Supplement type NDA /S-005 July 24, 2008 July 25, 2008 Changes Being Effected

Food and Drug Administration

DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers

Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products

February 2006 Procedural

Billing with National Drug Codes (NDCs) Frequently Asked Questions

Billing with National Drug Codes (NDCs) Frequently Asked Questions

FDA s Final Compliance Policy Guide for Marketed Unapproved Drugs Is Agency Enforcement at a Crossroads, or Stuck in a Traffic Circle

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation

Members covered under the Extended Family Planning (EFP) plan may not be eligible for all services. EFP is not a comprehensive benefit package.

Guidance for Industry Classifying Resubmissions in Response to Action Letters

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

Guidance for Industry

Guidance for Industry

Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO

Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program

Inspections, Compliance, Enforcement, and Criminal Investigations

Guidance for Industry

May 5, Dear Mr. Courtney:

Guidance for Industry

Establishment Registration SPL Technical Errors Training ebook

POLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR. Table of Contents

Request for Quality Metrics Guidance for Industry

Guidance for Industry and FDA Staff FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND Frequently Asked Questions

Guidance for Industry

RE: NDA: DICLEGIS (doxylamine succinate and pyridoxine hydrochloride) delayed-release tablets, for oral use MA # 350 WARNING LETTER

Instructions for Completing the Initial System Assessment for Upcoming HIPAA Changes Due Date: (specify date)

Enclosure A DEFINITIONS

New Chemical Entity Exclusivity Determinations for Certain Fixed- Combination Drug Products

Determination of Regulatory Review Period for Purposes of Patent Extension;

January 12, Dear Amy Yang:

Guidance Medication Guides Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS)

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification

CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity

Medical Billing and Agency Formal Disputes

Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.

Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products

Home Use Medical Device Electronic Labeling - Structured Product Labeling

Nevirapine 200 mg tablets WHOPAR part 5 09/2010, version 1.0 (Matrix Laboratories Ltd), HA396 LABELLING. Page 1 of 8

2014 Annual Report on Inspections of Establishments

August 21, TCM Associates Ltd Mr. Iain Alligan Technical Director 3 Hillgrove Business Park Nazeing Road Essex EN9 2HB United Kingdom

Providing Regulatory Submissions In Electronic Format Standardized Study Data

(k)Suminary k

Medical Gas Compliance Alert

DSCSA Updates and Readiness Check: Requirements for Dispensers and other Trading Partners

0 EC V-,) 133 Lj9a

Guidance for Industry

Global Unique Device Identification Database (GUDID) Guidance for Industry and Food and Drug Administration Staff

October 28, Cavex Holland Bv Mr. Richard Woortman Manager Technical Services Fustweg 5 Haarlem, 2031CJ The NETHERLANDS

Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA

Guidance for Industry

August 12, Oertli Instrumente AG Ms. Karin Rohr Head of Quality Management & Regulatory Affairs Hafnerwisenstrasse 4 CH 9442 Berneck Switzerland

The 505(b)(2) Drug Development Pathway:

TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES SUBCHAPTER H--MEDICAL DEVICES

November 20, Vascular Flow Technologies Ltd. Edwin Lindsay VP of QA/RA Prospect Business Centre, Gemini Cresent Dundee DD2 1TY United Kingdom

Drug Imports Exports Compliance

February 5, Dear Kristin Pabst,

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Connecticut Department of Social Services Medical Assistance Program Provider Bulletin. PB June 2008

April 7, Acclarent, Inc. Mr. James Patrick Garvey II Sr. Manager, Regulatory Affairs 1525-B O'Brien Drive Menlo Park, CA 94025

Combination Products Regulation in the United States

GENERAL INSTRUCTIONS

Q(K SVJM~jPagelIof 3

POLICY AND PROCEDURES OFFICE OF NEW DRUGS. NDAs and BLAs: Communication to Applicants of Planned Review Timelines.

Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection

Transcription:

The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily. 2016

0781-4103-52 Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium Labeler Sandoz Inc of Company corresponding to the labeler code segment of the ProductNDC. NDC Code 0781-4103-52 The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. Proprietary Drospirenone/Ethinyl Estradiol/Levomefolate Calcium and Levomefolate Calcium Also known as the trade name. It is the name of the product chosen by the labeler. 11 Digit NDC Code 00781-4103-52 It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format. Product NDC 0781-4103 The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. Product Type Non Proprietary Package Description Marketing Category HUMAN PRESCRIPTION DRUG Drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium 3 BLISTER PACK in 1 PACKAGE (0781-4103-52) > 1 KIT in 1 BLISTER PACK (0781-4103-15) NDA AUTHORIZED GENERIC Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE. Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. - 2 -

Application Number NDA022574 This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. part 341 ). For unapproved drugs, this field will be null. Start Marketing Date 20150801 This is the date that the labeler indicates was the start of its marketing of the drug product. Dosage Form KIT The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. - 3 -

Food and Drug Administration Center for Drug Evaluation and Research Office of Compliance, Immediate Office Drug Registration and Listing Team 10903 New Hampshire Ave Silver Spring, MD 20993-0002 Email: edrls@fda.hhs.gov - 4 -

For all questions regarding this bundle please contact Support@HIPAASpace.com. Also feel free to let us know about any suggestions or concerns. All additional information as well as customer support is available at http://www.hipaaspace.com. - 5 -